Noxopharm (ASX:NOX) - CEO, Dr Graham Kelly
CEO, Dr Graham Kelly
Sourced: Noxopharm
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Noxopharm (NOX) teams up with the US National Cancer Institute (NCI) to investigate more effective treatments for brain cancer
  • The collaboration was formed to evaluate a new family of anti-cancer drugs designed by Noxopharm scientist
  • According to NOX, the new drugs can block ‘helper’ growth signals coming from neighbouring healthy cell
  • Noxopharm said the first program will be focusing on brain cancer, with details of a separate pancreatic cancer program to be announced shortly
  • On the market this morning, Noxopharm is up 2.59 per cent, trading at 59.5 cents per share

Noxopharm (NOX) has teamed up with the US National Cancer Institute (NCI) to investigate more effective treatments for brain cancer.

The collaboration was formed to evaluate a new family of anti-cancer drugs designed by Noxopharm scientist.

According to NOX, the new drugs can block ‘helper’ growth signals coming from neighbouring healthy cell.

Those ‘helper’ growth signals are considered an important contributor to the highly aggressive nature of certain cancers, such as brain, pancreas and bile duct.

“Finding drugs that block these ‘helper’ signals in a tumour’s micro-environment has become a major new direction in oncology,” the company explained.

Noxopharm said the challenge is to block these signals without damaging their source, an issue vital in cases such as the brain.

However, the company believes it has achieved this objective in pre-clinical studies. It says the drug can potentially convert aggressive brain cancers in adults and children into slow-growing cancers which can be managed by other treatments such as surgery and radiotherapy.

Principal investigator at the Neuro-Oncology Branch at NCI is pleased with the partnership.

“We are enthusiastic about this collaboration that aims to find new targeted molecular therapies for patients affected by diseases in the central nervous system, particularly brain cancers,” he said.

Noxopharm CEO Graham Kelly said this principal is applicable to a wide range of highly aggressive cancers.

“Brain cancer is our first program, and a separate pancreatic cancer program is underway with details to be announced shortly,” Dr Kelly said.

On the market this morning, Noxopharm is up 2.59 per cent, trading at 59.5 cents per share at 11:28 am AEST.

NOX by the numbers
More From The Market Herald

" Nanoveu (ASX:NVU) signs MoU to establish JV in India

Nanoveu (ASX:NVU) has signed a memorandum of understanding (MoU) with Alan Scott Industries to establish a…
The Market Herald Video

" NeuroScientific Biopharmaceuticals (ASX:NSB) recruits first trial subject

NeuroScientific Biopharmaceuticals (ASX:NSB) has recruited its first subject for an early-phase clinical trial.
The Market Herald Video

" Creso Pharma (ASX:CPH) eyes entrance to Taiwanese animal healthcare market

Creso Pharma (ASX:CPH) has progressed activities to introduce Sierra Sage Herbs (SSH) products to the Taiwanese…

" Cann Group (ASX:CAN) granted GMP manufacturing licence for Mildura

Cann Group (ASX:CAN) has been granted a good manufacturing practice (GMP) licence for its Mildura facility…